Skip to main content
. 2021 Nov 10;10(11):1796. doi: 10.3390/antiox10111796

Figure 4.

Figure 4

ψ-GSH treatment reduces reactive astrogliosis and microglial reactivity in symptomatic 10- and 14-mo APP/PS1 mice. (a) Representative images of reactive astrocytes visualized by GFAP antibody in dentate gyrus of 14-mo NTG and APP/PS1 mice. Scale bar, 100 μm. (b) Quantification of GFAP staining in S1BF of the 10-, 14-mo cohorts. (c) Quantification of GFAP staining in the hippocampus of the 10-, 14-mo cohorts. (d) Representative images of microglia visualized using Iba1 antibody in S1BF cortex of 14-mo NTG and APP/PS1 mice. Scale bar, 100 μm. (e) Quantification of Iba1 staining in S1BF of the 10-, 14-mo cohorts. (f) Quantification of Iba1 staining in the hippocampus of the 10-, 14-mo cohorts. Data are presented as mean ± S.E.M. For comparisons between NTG, saline-, and ψ-GSH-treated APP/PS1 groups, a one-way ANOVA with Tukey’s post-hoc test was used for data analysis. * p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.001.